ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Lexeo Therapeutics Inc

Lexeo Therapeutics Inc (LXEO)

13.43
0.22
(1.67%)
At close: May 07 4:00PM
13.43
0.22
( 1.67% )
After Hours: 4:30PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
13.43
Bid
11.43
Ask
16.36
Volume
100,116
12.98 Day's Range 13.635
9.00 52 Week Range 22.33
Market Cap
Previous Close
13.21
Open
13.25
Last Trade Time
16:10:08
Financial Volume
$ 1,320,369
VWAP
13.1884
Average Volume (3m)
122,181
Shares Outstanding
26,668,956
Dividend Yield
-
PE Ratio
-5.39
Earnings Per Share (EPS)
-2.49
Revenue
-
Net Profit
-66.39M

About Lexeo Therapeutics Inc

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene t... Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
,
Founded
1970
Lexeo Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker LXEO. The last closing price for Lexeo Therapeutics was $13.21. Over the last year, Lexeo Therapeutics shares have traded in a share price range of $ 9.00 to $ 22.33.

Lexeo Therapeutics currently has 26,668,956 shares outstanding. The market capitalization of Lexeo Therapeutics is $357.90 million. Lexeo Therapeutics has a price to earnings ratio (PE ratio) of -5.39.

LXEO Latest News

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined...

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate...

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined...

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined...

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.29.8119378577312.2313.54512.1314155812.75240921CS
40.53.8669760247512.9315.0611.5712436412.53085483CS
12-2.15-13.799743260615.5817.1111.5712218114.2689957CS
262.9327.904761904810.522.339.3211415614.03784253CS
523.9341.36842105269.522.33912178213.73746344CS
1563.9341.36842105269.522.33912178213.73746344CS
2603.9341.36842105269.522.33912178213.73746344CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NCINeo Concept International Group Holdings Ltd
$ 1.29
(31.23%)
3.49M
INODInnodata Inc
$ 8.62
(27.61%)
151.01k
HUBCWHub Cyber Security Ltd
$ 0.029
(25.54%)
300
RPTXRepare Therapeutics Inc
$ 4.00
(21.95%)
7.19k
CLOVClover Health Investments Corporation
$ 0.8888
(20.11%)
2.15M
TMCITreace Medical Concepts Inc
$ 5.80
(-47.84%)
675.75k
LZLegalZoom com Inc
$ 10.12
(-16.98%)
121.56k
ZIZoomInfo Technologies Inc
$ 13.50
(-15.73%)
940.16k
DHDefinitive Healthcare Corporation
$ 6.11
(-15.72%)
11.67k
VLCNVolcon Inc
$ 0.25
(-15.23%)
512.9k
RIVNRivian Automotive Inc
$ 9.65
(-5.85%)
11.49M
LYFTLyft Inc
$ 17.61
(6.08%)
7M
PEGYPineapple Energy Inc
$ 0.0749
(-1.06%)
6.07M
FFIEFaraday Future Intelligent Electric Inc
$ 0.04345
(-0.57%)
4.98M
NCINeo Concept International Group Holdings Ltd
$ 1.29
(31.23%)
3.49M

Discussion

View Full Feed
GARYM1 GARYM1 5 minutes ago
Where are you getting 20 mill a Quarter Company recently put out numbers stating 16 mill 2024 25 mill 2025 and 40 mill 2026
SEV
janice shell janice shell 5 minutes ago
do you ever check the dates on stuff before you post it?

He doesn't seem to. I've noticed that in the past. It begs the question: Does he even read any of this stuff? Or is he just posting headlines that please him?
Nemesis18 Nemesis18 5 minutes ago
Pre-Revenue…

Ie.. https://investorshub.advfn.com/uimage/uploads/2024/5/7/xi%5Bed6ECDD2C7-C8EF-4684-A2A2-B9315F74A577.jpeg
NWBO
cjstocksup cjstocksup 5 minutes ago
https://x.com/elonmusk/status/1787910522547093951
dealerschool2006 dealerschool2006 5 minutes ago
It's too bad the author didn't mention #freeportlng as being the real reason NG has been going up...the export facility is now operational...we just don't know how reliable the operation is...
davidsson10 davidsson10 5 minutes ago
"Production values."
Westcoastplaya Westcoastplaya 6 minutes ago
Either you just made that up, or you’re Kramer or in contact with Kramer.

I follow occom’s razor so you’re probably just a liar as opposed to being Kramer or in contact with Kramer.


Quote
“What about when the SEC says Kramer never shorted the stocks tha
DBMM
stock1ace1 stock1ace1 6 minutes ago
Read the filings last filing states 30 mill o/s theres way more now


Our ordinary shares are listed on the Nasdaq Capital Market under the symbol “HOLO.” On January 24, 2024, the highest closing price of our ordinary shares during the last 60 days was $0.95 per share on Novemb
HOLO
MetaMonster MetaMonster 6 minutes ago
These dirty Chinese short rats want to screw US investors, Hell is where they all belong, going to blow the dirty rats out of their hole
HOLO
Boris the Spider Boris the Spider 6 minutes ago
May is shaping up to be very important.
Libor has been eerily quiet. If rumors mean anything something could be brewing. Id gladly take 100b.
But the first settlement could be BBA, not JPM. Lets see if the judge combines them so Dimon can play hide the sausage.
The other ques
JPM
Hummingbird2 Hummingbird2 7 minutes ago
https://x.com/BasileEsq/status/1787906592144236656?t=zrtUw9LhGQvMahmo63Fc-A&s=09
GTII
trash1 trash1 7 minutes ago
au futures.. time to go much higher now
DOLLF
theorysuit theorysuit 7 minutes ago
For the most part, they do hold calls and also put out a PR with the Qtrly results where they kind of summarize what goes on in the call. In summary, most prerevenue bios do both a call and PR that summarizes the info of the call. That is definitely the norm. Don't let these pumpers tell you a
NWBO
gshores gshores 7 minutes ago
Its fine to sell but when u sell and then try to bash the company after you sell to get in again. Sick and selfish. Worst type of human. Thats idiotic
SPZI
jimr1717 jimr1717 7 minutes ago
There is only 1 Fool that is Fooled.
ATMH
marylandstockguy marylandstockguy 7 minutes ago
Haha what a shocker right? I thought all these plays were diamonds in the rough? Ugggh…as you say welcome to the Wild West
GTCH
Invest-in-America Invest-in-America 8 minutes ago
CLOV, Clover Health (3%): $0.74; 14%, 20%, ; XXX 00%, ; (Post-M) 5-7-24 news revs. up; "Physician-Enabled" seniors care, & insurance, TN.

PS: MY silly notes, above --- YOU figure it out. (Lacks the COLOR I put in, though!!)

https://media.giphy.com/media/v1.Y2lkPTc5
CLOV
JALchicago JALchicago 8 minutes ago
No, I meant personal.
ACRL
dealerschool2006 dealerschool2006 8 minutes ago
SHAAAAADAUP!!!! I don't care who you are or how right or wrong you are...I'm playin my own game just like the next clown...this isn't a competition...it's about helping each other succeed...
BOIL
jimr1717 jimr1717 8 minutes ago
It will be more “amazing” soon.
CVNA
Cabinmoney Cabinmoney 8 minutes ago
Yes
RXMD
Ecomike Ecomike 9 minutes ago
Bad news for IFUS factless fraud post bashers:

https://pbs.twimg.com/media/GM5_cRMaEAAGSph?format=jpg&name=small
IFUS
GBR GBR 9 minutes ago
agree. But they seem to have some loyal customers like CBS and Iheart. Why does RS stay at the helm? With aiWARE being nothing significant, not taking off like they envisioned, why doesn't he pass the baton to another CEO. Particularly since he dropped his salary to a buck. So he's basically ge
VERI
SSKILLZ1 SSKILLZ1 9 minutes ago
~~COMPX 5/8/2024~~~~~~~

Previous Close

16,332.56 -16.69

16199 SSKILLZ1
COMP

Your Recent History

Delayed Upgrade Clock